| | Results of Zibotentan Phase III-trial in castration resistant prostate cancer | | | AstraZeneca today announced that a study evaluating zibotentan for the treatment of men with metastatic castration resistant prostate cancer (CRPC) did not show a significant improvement in the primary endpoint of overall survival. | |  View full press release | | | This email has been sent via AstraZeneca's email alert service. Update your email preferences, unsubscribe from this service or contact us. | | | |
No comments:
Post a Comment